awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38256348-A8958007-3299-4D8D-84F7-61CC69117611
Q38256348-A8958007-3299-4D8D-84F7-61CC69117611
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38256348-A8958007-3299-4D8D-84F7-61CC69117611
Profile of selumetinib and its potential in the treatment of melanoma.
P2860
Q38256348-A8958007-3299-4D8D-84F7-61CC69117611
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38256348-A8958007-3299-4D8D-84F7-61CC69117611
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
63e7cbd53d4d0b36a3e0ec5438df78a6285482bf
P2860
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors